Clinical Trial Update: HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection [Phase 2]

View source ↗

Summary

Phase 2 trial of HepeX-B for end-stage liver disease due to hepatitis B infection in post-transplant patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Liver Disease
• Hepatitis B

Drugs mentioned

• HepeX-B

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Hepatitis B, Liver Transplantation | Phase 2 | Status: TERMINATED